HER3, serious partner in crime: Therapeutic approaches and potential biomarkers for effect of HER3-targeting

Pharmacology and Therapeutics

Volumn 143, Issue 1, 2014, Pages 1-11

  Kol, Arjan ^a   Terwisscha Van Scheltinga, Anton G T ^a   Timmer Bosscha, Hetty ^a   Lamberts, Laetitia E ^a   Bensch, Frederike ^a   De Vries, Elisabeth G E ^a   Schröder, Carolina P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Biomarkers; HER3; Molecular imaging; Monoclonal antibodies; Resistance; Tyrosine kinase inhibitors

Indexed keywords

ANTIBODY; BISPECIFIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN; PROTEIN HER3; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; AZD 8931; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB3 PROTEIN, HUMAN; MM-111; QUINAZOLINE DERIVATIVE;

ARTICLE; DRUG TARGETING; GENE OVEREXPRESSION; MOLECULAR IMAGING; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN TARGETING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; HUMAN; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, BISPECIFIC; BIOLOGICAL MARKERS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; QUINAZOLINES; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 84898850543     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2014.01.005     Document Type: Review

References (120)

1. V.K. Anagnostou, A.W. Welsh, J.M. Giltnane, S. Siddiqui, C. Liceaga, and M. Gustavson et al. Analytic variability in immunohistochemistry biomarker studies Cancer Epidemiol Biomarkers Prev 19 2010 982 991
2. L. Andrique, D. Fauvin, M. El Maassarani, H. Colasson, B. Vannier, and P. Séité ErbB3(80 kDa), a nuclear variant of the ErbB3 receptor, binds to the Cyclin D1 promoter to activate cell proliferation but is negatively controlled by p14ARF Cell Signal 24 2012 1074 1085
3. S.Y. Archer, and R.A. Hodin Histone acetylation and cancer Curr Opin Genet Dev 9 1999 171 174 (Pubitemid 29158551)
4. B. Balachandran, C. Chabot, S. Hamel, C.T. Chan, S. Kane, and M. Buchanan et al. Overcoming Trastuzumab resistance with the novel pan-erbb inhibitor AZD8931 Cancer Res 72 8 Suppl. 2012 (Abstract nr 770)
5. J. Baselga, I. Bradbury, H. Eidtmann, S. Di Cosimo, E. de Azambuja, and C. Aura et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet 379 2012 633 640
6. J. Baselga, J. Cortés, S.A. Im, E. Clark, A. Kiermaier, and G. Ross Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC) Cancer Res 72 24 Suppl. 2012 (Abstract nr S5-1)
7. J. Baselga, J. Cortés, S.B. Kim, S.A. Im, R. Hegg, and Y.H. Im et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 2012 109 119
8. J. Baselga, R. Hegg, M.V. Losada, T. Vidaurre, A. Lluch, and K. Petrakova A phase II randomized placebo-controlled study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, plus paclitaxel (P) vs P alone in patients (pts) with low HER2-expressing advanced breast cancer (BC) (THYME) Proc AACR 2013 (Abstract nr LB-146)
9. J. Baselga, and S.M. Swain Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 Nat Rev Cancer 9 2009 463 475
10. J. Baum, B. Johnson, S. Adams, J. Tang, S. Iadevaia, and B. Schoeberl et al. MM-141, a novel bispecific antibody co-targeting IGF-1R and ErbB3, inhibits PI3K/Akt/mTOR pro-survival signaling in preclinical cancer models Eur J Cancer 48 6 Suppl. 2012 97 (Abstract nr 316)
11. R.R. Beerli, D. Graus-Porta, K. Woods-Cook, X. Chen, Y. Yarden, and N.E. Hynes Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2 Mol Cell Biol 15 1995 6496 6505
12. M.D. Begnami, E. Fukuda, J.H. Fregnani, S. Nonogaki, A.L. Montagnini, and W.L. Jr da Costa et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome J Clin Oncol 29 2011 3030 3036
13. K.L. Blackwell, H.J. Burstein, A.M. Storniolo, H.S. Rugo, G. Sledge, and G. Aktan et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study J Clin Oncol 30 2012 2585 2592
14. J. Boudeau, D. Miranda-Saavedra, G.J. Barton, and D.R. Alessi Emerging roles of pseudokinases Trends Cell Biol 16 2006 443 452 (Pubitemid 44293399)
15. E. Buck, A. Eyzaguirre, J.D. Haley, N.W. Gibson, P. Cagnoni, and K.K. Iwata Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity Mol Cancer Ther 5 2006 2051 2059 (Pubitemid 44336577)
16. M.R. Campbell, D. Amin, and M.M. Moasser HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy Clin Cancer Res 16 2010 1373 1383
17. A. Cervantes, D. Roda, N. Tarazona, S. Roselló, and J.A. Pérez-Fidalgo Current questions for the treatment of advanced gastric cancer Cancer Treat Rev 39 2013 60 67
18. A. Cervantes-Ruiperez, D. Juric, M. Hidalgo, W.A. Messersmith, G.R. Blumenschein, and J. Baselga et al. A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: expansion cohorts J Clin Oncol 30 2012 (Suppl.; abstr 2568)
19. A. Chakrabarty, V. Sánchez, M.G. Kuba, C. Rinehart, and C.L. Arteaga Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors Proc Natl Acad Sci U S A 3 2011 3 8
20. S. Chandarlapaty, A. Sawai, M. Scaltriti, V. Rodrik-Outmezguine, O. Grbovic-Huezo, and V. Serra et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity Cancer Cell 19 2011 58 71
21. C.G. Chiu, H. Masoudi, S. Leung, D.K. Voduc, B. Gilks, and D.G. Huntsman et al. HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients Ann Surg 251 2010 1107 1116
22. A. Citri The deaf and the dumb: the biology of ErbB-2 and ErbB-3 Exp Cell Res 284 2003 54 65 (Pubitemid 36342255)
23. J. Cortes, J. Baselga, P. Fumoleau, K.A. Gelmon, G. Ross, and V. McNally et al. Pertuzumab and trastuzumab: exploratory biomarker correlations with clinical benefit in patients with metastatic HER2-positive breast cancer J Clin Oncol 28 2010 (Suppl.; abstr 1066)
24. M. Curley, A. Kalra, A. Fulgham, D. Xiao, J. Allen, and M. Wainszelbaum et al. MM-121, an anti-ErbB3 antibody, inhibits PI3K/AKT signaling and viability in platinum-resistant ovarian cells and in primary ascites derived from chemo-resistant ovarian cancer patients Eur J Cancer 48 6 Suppl. 2012 43 44 (Abstract nr 141)
25. J. De Greve, T. Moran, M. Graas, D. Galdermans, P. Vuylsteke, and J. Canon et al. Phase II study of afatinib; an irreversible ErbB family blocker; in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients J Clin Oncol 31 2013 (Suppl.; abstr 8063)
26. J.A. Engelman, P.A. Jänne, C. Mermel, J. Pearlberg, T. Mukohara, and C. Fleet et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines Proc Natl Acad Sci USA 102 2005 3788 3793 (Pubitemid 40354690)
27. J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, and J.O. Park et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043 (Pubitemid 46799492)
28. D.J. Freeman, S. Ogbagabriel, J. Bready, J.-R. Sun, R. Radinsky, and T. Hettmann U3-1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates in vitro and in vivo efficacy in the FaDu model of human squamous cell carcinoma of the head and neck (SCCHN) Mol Cancer Ther 10 11 Suppl. 2011 (Abstract nr A182)
29. A.P. Garner, C.U. Bialucha, E.R. Sprague, J.T. Garrett, Q. Sheng, and S. Li et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin Cancer Res 73 2013 6024 6035
30. A. Garner, Q. Sheng, U. Bialucha, D. Chen, Y. Chen, and R. Das et al. LJM716: an anti-HER3 antibody that inhibits both HER2 and NRG driven tumor growth by trapping HER3 in the inactive conformation Cancer Res 72 8 Suppl. 2012 (Abstract nr 2733)
31. J.T. Garrett, and C.L. Arteaga Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications Cancer Biol Ther 11 2011 793 800
32. J.T. Garrett, M.G. Olivares, C. Rinehart, N.D. Granja-Ingram, V. Sánchez, and A. Chakrabarty et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase Proc Natl Acad Sci U S A 108 2011 5021 5026
33. J.T. Garrett, C.R. Sutton, M.G. Kuba, R.S. Cook, and C.L. Arteaga Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function Clin Cancer Res 19 2013 610 619
34. J.T. Garrett, C.R. Sutton, R. Kurupi, C.U. Bialucha, S.A. Ettenberg, and S.D. Collins et al. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers Cancer Res 73 2013 6013 6023
35. S.B. Gaykema, A.H. Brouwers, S. Hovenga, M.N. Lub-de Hooge, E.G. de Vries, and C.P. Schröder Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer J Clin Oncol 30 2012 74 75
36. L. Gianni, G. Bianchini, A. Kiermaier, G. Bianchi, Y.-H. Im, and T. Pienkowski et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): biomarker analyses of a 4-arm randomized phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC) Cancer Res 71 24 Suppl. 2011 (Abstract nr S5-1)
37. L. Gianni, T. Pienkowski, Y.H. Im, L. Roman, L.M. Tseng, and M.C. Liu et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 2012 25 32
38. J.M. Giltnane, C.B. Moeder, R.L. Camp, and D.L. Rimm Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort Cancer 115 2009 2400 2409
39. D. Graus-Porta, R.R. Beerli, J.M. Daly, and N.E. Hynes ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling EMBO J 16 1997 1647 1655 (Pubitemid 27151960)
40. L.M. Grøvdal, J. Kim, M.R. Holst, S.L. Knudsen, M.V. Grandal, and B. van Deurs EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells Cell Signal 24 2012 296 301
41. N. Hanada, H.-W. Lo, C.-P. Day, Y. Pan, Y. Nakajima, and M.-C. Hung Co-regulation of B-Myb expression by E2F1 and EGF receptor Mol Carcinog 45 2006 10 17 (Pubitemid 43122365)
42. R. Harris, E. Chung, and R.J. Coffey EGF receptor ligands Exp Cell Res 284 2003 2 13 (Pubitemid 36331964)
43. M. Hayashi, M. Inokuchi, Y. Takagi, H. Yamada, K. Kojima, and J. Kumagai et al. High expression of HER3 is associated with a decreased survival in gastric cancer Clin Cancer Res 14 2008 7843 7849
44. C. Henry, C. Geslin, A.M. Blanchet, C. Nicolazzi, G. Garcia, and L. Vincent et al. MM-121 (SAR256212), an anti-ErbB3 monoclonal antibody, shows synergistic tumor growth inhibition in combination with a pan-PI3K inhibitor or a microtubule inhibitor through ErbB3 expression modulation Eur J Cancer 48 6 Suppl. 2012 99 (Abstract nr 325)
45. D.M. Hickinson, T. Klinowska, G. Speake, J. Vincent, C. Trigwell, and J. Anderton et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer Clin Cancer Res 16 2010 1159 1169
46. T. Holbro, R.R. Beerli, F. Maurer, M. Koziczak, C.F. Barbas, and N.E. Hynes The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation Proc Natl Acad Sci U S A 100 2003 8933 8938 (Pubitemid 36899201)
47. X. Huang, L. Gao, S. Wang, C.K. Lee, P. Ordentlich, and B. Liu HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression Cancer Res 69 2009 8403 8411
48. S. Huang, C. Li, E.A. Armstrong, C.R. Peet, J. Saker, and L.C. Amler et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation Cancer Res 73 2013 824 833
49. X. Huang, S. Wang, C.K. Lee, X. Yang, and B. Liu HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance Cancer Lett 307 2011 72 79
50. I.R. Hutcheson, L. Goddard, D. Barrow, R.A. McClelland, H.E. Francies, and J.M. Knowlden et al. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1 Breast Cancer Res 13 2011 R29
51. Y. Ito, T. Takeda, M. Sakon, M. Tsujimoto, S. Higashiyama, and K. Noda et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma Br J Cancer 84 2001 1377 1383 (Pubitemid 32522107)
52. B.S. Jaiswal, N.M. Kljavin, E.W. Stawiski, E. Chan, C. Parikh, and S. Durinck et al. Oncogenic ERBB3 mutations in human cancers Cancer Cell 23 2013 603 617
53. S. Johnston, M. Trudeau, B. Kaufman, H. Boussen, K. Blackwell, and P. LoRusso et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy J Clin Oncol 26 2008 1066 1072
54. I.H. Koumakpayi, J.S. Diallo, C. Le Page, L. Lessard, M. Gleave, and L.R. Bégin et al. Expression and nuclear localization of ErbB3 in prostate cancer Clin Cancer Res 12 2006 2730 2737
55. T. Kouzarides Histone acetylases and deacetylases in cell proliferation Curr Opin Genet Dev 9 1999 40 48 (Pubitemid 29080385)
56. M.H. Kraus, W. Issing, T. Miki, N.C. Popescu, and S.A. Aaronson Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors Proc Natl Acad Sci U S A 86 1989 9193 9197 (Pubitemid 20010391)
57. C.H. Lee, D.G. Huntsman, M.C. Cheang, R.L. Parker, L. Brown, and P. Hoskins et al. Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma Int J Gynecol Pathol 24 2005 147 152 (Pubitemid 40389539)
58. D. Li, L. Ambrogio, T. Shimamura, and S. Kubo BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27 2008 4702 4711
59. J.S. Liles, J.P. Arnoletti, A.V. Kossenkov, A. Mikhaylina, A.R. Frost, and P. Kulesza et al. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma Br J Cancer 105 2011 523 533
60. S.Y. Lin, K. Makino, W. Xia, A. Matin, Y. Wen, and K.Y. Kwong et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor Nat Cell Biol 3 2001 802 808 (Pubitemid 32842685)
61. N.U. Lin, E.P. Winer, D. Wheatley, L.A. Carey, S. Houston, and D. Mendelson et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab Breast Cancer Res Treat 133 2012 1057 1065
62. C.A. Lipinski, N.L. Tran, E. Menashi, C. Rohl, J. Kloss, and R.C. Bay et al. The tyrosine kinase Pyk2 promotes migration and invasion of gGlioma cells Neoplasia 7 2005 435 445 (Pubitemid 40791863)
63. A. Lipton, L. Goodman, K. Leitzel, J. Cook, J. Sperinde, and M. Haddad et al. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer Breast Cancer Res Treat 141 2013 43 53
64. H.W. Lo, S.C. Hsu, M. Ali-Seyed, M. Gunduz, W. Xia, and Y. Wei et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway Cancer Cell 7 2005 575 589 (Pubitemid 40799250)
65. S. Makhija, L.C. Amler, D. Glenn, F.R. Ueland, M.A. Gold, and D.S. Dizon Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer J Clin Oncol 28 2010 1215 1223
66. C.F. McDonagh, A. Huhalov, B.D. Harms, S. Adams, V. Paragas, and S. Oyama et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3 Mol Cancer Ther 11 2012 582 593
67. 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts J Nucl Med 50 2009 1340 1348
68. K. Meetze, S. Tyler, K. Clark, E. Mazsa, A. Delpero, and J. Gyuris The anti-tumor activity of the ERBB3 inhibitory antibody AV-203 in patient derived tumor explant models Eur J Cancer 48 6 Suppl. 2012 126 (Abstract nr 414)
69. G. Meneses-Lorente, L. Kolm, M. Thomas, T. Friess, S. Bader, and C.B. Meille Preclinical pharmacokinetics of GE-huMab-HER3, a novel humanized, glycoengineered anti-HER3 antibody using PHER3/HER3 ratio as pharmacodynamics (PD) marker Eur J Cancer 48 6 Suppl. 2012 116 117 (Abstract nr 382)
70. D. Meulendijks, M.P.J.K. Lolkema, E.E. Voest, M.J. De Jonge, S. Sleijfer, and J.H.M. Schellens et al. A first-in-human trial of RG7116; a glycoengineered monoclonal antibody targeting HER3; in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein J Clin Oncol 31 2013 (Suppl.; abstr 2522)
71. C. Mirschberger, C.B. Schiller, M. Schräml, N. Dimoudis, T. Friess, and C.A. Gerdes et al. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation Cancer Res 73 2013 5183 5194
72. S. Modi, A. Stopeck, H. Linden, D. Solit, S. Chandarlapaty, and N. Rosen HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab Clin Cancer Res 17 2011 5132 5139
73. A. Mukherjee, Y. Badal, X.T. Nguyen, J. Miller, A. Chenna, and H. Tahir et al. Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins PLoS One 6 2011 e16443
74. M. Offterdinger, C. Schöfer, K. Weipoltshammer, and T.W. Grunt c-ErbB-3: a nuclear protein in mammary epithelial cells J Cell Biol 157 2002 929 939 (Pubitemid 34839768)
75. 89Zr-trastuzumab-F(ab′)(2) uptake in SKBR3 tumor xenografts Mol Pharm 9 2012 2995 3002
76. 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft Eur J Cancer 46 2010 678 684
77. P.J. Perik, M.N. Lub-De Hooge, J.A. Gietema, W.T. van der Graaf, M.A. de Korte, and S. Jonkman et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer J Clin Oncol 24 2006 2276 2282 (Pubitemid 46630657)
78. M. Pickl, T. Friess, B. Bossenmaier, C.-H. Ooi, G. Mills, and S. Bader Identification of potential pharmacodynamic markers for HER3 targeted cancer treatment by a multi-technology approach Cancer Res 72 8 Suppl. 2012 (Abstract nr 3603)
79. G.D. Plowman, G.S. Whitney, M.G. Neubauer, J.M. Green, V.L. McDonald, and G.J. Todaro et al. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene Proc Natl Acad Sci U S A 87 1990 4905 4909
80. N. Prenzel, O.M. Fischer, S. Streit, S. Hart, and A. Ullrich The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification Endocr Relat Cancer 8 2001 11 31 (Pubitemid 32520251)
81. S.A. Prigent, N.R. Lemoine, C.M. Hughes, G.D. Plowman, C. Selden, and W.J. Gullick Expression of the c-erbB-3 protein in normal human adult and fetal tissues Oncogene 7 1992 1273 1278
82. T. Rajkumar, and W.J. Gullick A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines Br J Cancer 70 1994 459 465 (Pubitemid 24268548)
83. E.J. Razumienko, D.A. Scollard, and R.M. Reilly Small-Animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates J Nucl Med 53 2012 1943 1950
84. M. Reschke, D. Mihic-Probst, E.H. van der Horst, P. Knyazev, P.J. Wild, and M. Hutterer et al. HER3 is a determinant for poor prognosis in melanoma Clin Cancer Res 14 2008 5188 5197
85. D. Richards, F. Braiteh, S. Anthony, W. Edenfield, B. Hellerstedt, and R. Raju A phase 1 study of MM-111; a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2 positive solid tumors Ann Oncol 23 9 Suppl. 2012 (Abstract nr 496P)
86. G. Schaefer, L. Haber, L.M. Crocker, S. Shia, L. Shao, and D. Dowbenko et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies Cancer Cell 20 2011 472 486
87. T. Schneider-Merck, J.J. Lammerts van Bueren, S. Berger, K. Rossen, P.H. van Berkel, and S. Derer et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage J Immunol 184 2011 512 520
88. B. Schoeberl, A.C. Faber, D. Li, M.-C. Liang, K. Crosby, and M. Onsum et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation Cancer Res 70 2010 2485 2494
89. W. Schormann Untersuchung der subzellulären Lokalisation der Rezeptortyrosinkinase HER-3 Accessed June 12, 2013, from http://hdl.handle.net/ 2003/25935 2008
90. C.P. Schröder, J.V. Pedersen, S. Chua, C. Swanton, M. Akimov, and S. Ide et al. Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+ or ER + metastatic breast cancer J Clin Oncol 29 2011 (Suppl.; abstr e11024)
91. M.A. Şendur, S. Aksoy, and N. Zengin Pertuzumab plus trastuzumab in metastatic breast cancer N Engl J Med 366 2012 1348
92. N.V. Sergina, M. Rausch, D. Wang, J. Blair, B. Hann, and K.M. Shokat et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 Nature 445 2007 437 441 (Pubitemid 46160912)
93. V. Serra, M. Scaltriti, L. Prudkin, P.J. Eichhorn, Y.H. Ibrahim, and S. Chandarlapaty et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer Oncogene 30 2011 2547 2557
94. D.S. Shames, J. Carbon, K. Walter, A.M. Jubb, C. Kozlowski, and T. Januario et al. High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck PLoS One 8 2013 e56765
95. 64Cu - DOTA - AMG 888 (U3-1287) in control and tumor bearing mice using biodistribution and microPET imaging Proc World Molecular Imaging Congress 2011 (Abstract nr T206)
96. Q. Sheng, X. Liu, E. Fleming, K. Yuan, H. Piao, and J. Chen et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells Cancer Cell 17 2010 298 310
97. F. Shi, S.E. Telesco, Y. Liu, R. Radhakrishnan, and M.A. Lemmon ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation Proc Natl Acad Sci U S A 107 2010 7692 7697
98. H. Shyhmin, L. Chunrong, X.S. Mark, and M.H. Paul MEHD7945A, an EGFR/ErbB3 dual specific antibody, overcomes acquired resistance to EGFR inhibitors in head and neck and lung tumors Cancer Res 71 1 Suppl. 2011 (Abstract nr 637)
99. B.J. Simpson, J. Weatherill, E.P. Miller, A.M. Lessells, S.P. Langdon, and W.R. Miller C-erbB-3 protein expression in ovarian tumours Br J Cancer 71 1995 758 762
100. F. Solca, G. Dahl, A. Zoephel, G. Bader, M. Sanderson, and C. Klein et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker J Pharmacol Exp Ther 343 2012 342 350
101. D.B. Solit, A.D. Basso, A.B. Olshen, H.I. Scher, and N. Rosen Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to taxol Cancer Res 63 2003 2139 2144 (Pubitemid 36538618)
102. D.B. Solit, F.F. Zheng, M. Drobnjak, P.N. Münster, B. Higgins, and D. Verbel et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts Clin Cancer Res 8 2002 986 993 (Pubitemid 34517631)
103. M. Takikita, R. Xie, J.Y. Chung, H. Cho, K. Ylaya, and S.M. Hong et al. Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma J Transl Med 9 2011 126
104. B. Tanner, D. Hasenclever, K. Stern, W. Schormann, M. Bezler, and M. Hermes et al. ErbB-3 predicts survival in ovarian cancer J Clin Oncol 24 2006 4317 4323 (Pubitemid 46630790)
105. 89Zr-GE-huMAb-HER3 Eur J Cancer 48 6 Suppl. 2010 96 97
106. S. Tovey, B. Dunne, C.J. Witton, A. Forsyth, T.G. Cooke, and J.M. Bartlett Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 11 2005 4835 4842 (Pubitemid 41557203)
107. E. Trocmé, D. Mougiakakos, C.C. Johansson, C. All-Eriksson, M.A. Economou, and O. Larsson et al. Nuclear HER3 is associated with favorable overall survival in uveal melanoma Int J Cancer 130 2012 1120 1127
108. M.S. Tsai, L.A. Shamon-Taylor, I. Mehmi, C.K. Tang, and R. Lupu Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer Oncogene 22 2003 761 768 (Pubitemid 36269290)
109. E. Tzahar, H. Waterman, X. Chen, G. Levkowitz, D. Karunagaran, and S. Lavi et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor Mol Cell Biol 16 1996 5276 5287 (Pubitemid 26315047)
110. E.H. van der Horst, I. Weber, and A. Ullrich Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: novel heregulin/HER3-stimulated signaling pathway in glioma Int J Cancer 113 2005 689 698 (Pubitemid 40101248)
111. J. Wallweber, A. Chenna, R. Ravanera, W. Huang, D. Stathas, and G. Marshall Profiling HER3/ErbB3 activation in formalin-fixed, paraffin-embedded (FFPE) breast tumor samples that express high and low HER2/ErbB2 levels using proximity-based immunoassays Proc AACR 2013 (Abstract nr 3029)
112. S. Wang, X. Huang, C.-K. Lee, and B. Liu Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of survivin Oncogene 29 2010 4225 4236
113. S.C. Wang, H.C. Lien, W. Xia, I.F. Chen, H.W. Lo, and Z. Wang et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2 Cancer Cell 6 2004 251 261 (Pubitemid 39222038)
114. T.R. Wilson, D.Y. Lee, L. Berry, D.S. Shames, and J. Settleman Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers Cancer Cell 20 2011 158 172
115. S.E. Witta, V. Franekova, K. Yoshida, I. Igolnikov, B. Frederick, and M. Varella-Garcia et al. Synergistic effect of SNDX-275 with lapatinib or erlotinib in breast, lung, or head and neck cancer cell lines expressing HER-2 J Clin Oncol 27 2009 (Suppl.; abstr e14566)
116. Y. Yamashita-Kashima, S. Iijima, K. Yorozu, K. Furugaki, M. Kurasawa, and M. Ohta et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models Clin Cancer Res 17 2011 5060 5070
117. C.H. Yeon, and M.D. Pegram Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer Invest New Drugs 23 2005 391 409 (Pubitemid 41160088)
118. E.S. Yi, D. Harclerode, M. Gondo, M. Stephenson, R.W. Brown, and M. Younes et al. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas Mod Pathol 10 1997 142 148 (Pubitemid 27110039)
119. K. Zhang, J. Sun, N. Liu, D. Wen, D. Chang, and A. Thomason et al. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2 J Biol Chem 271 1996 3884 3890 (Pubitemid 26065710)
120. D.B. Zimonjic, L. Rezanka, J.A. DiPaolo, and N.C. Popescu Refined localization of the erbB-3 proto-oncogene by direct visualization of FISH signals on LUT-inverted and contrast-enhanced digital images of DAPI-banded chromosomes Cancer Genet Cytogenet 80 1995 100 102